CRDF
Cardiff Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRDF
Cardiff Oncology, Inc.
A clinical-stage biotechnology company that develops novel therapies for a range of cancers
Biological Technology
04/26/2002
05/29/2012
NASDAQ Stock Exchange
33
12-31
Common stock
11055 Flintkote Avenue, San Diego, California 92121
--
Cardiff Oncology, Inc., was incorporated in Florida on April 26, 2002. The company is a clinical-stage biotechnology company that utilizes PLK1 inhibition, a well-proven oncology drug target, to develop new therapies across a range of unmet medical needs for cancer. The company aims to target tumor vulnerability through a therapeutic combination of onvansertib, the company's oral and highly selective PLK1 inhibitors, and standard of care therapies.
Company Financials
EPS
CRDF has released its 2025 Q3 earnings. EPS was reported at -0.17, versus the expected -0.21, beating expectations. The chart below visualizes how CRDF has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRDF has released its 2025 Q3 earnings report, with revenue of 120.00K, reflecting a YoY change of -27.27%, and net profit of -11.26M, showing a YoY change of 5.04%. The Sankey diagram below clearly presents CRDF's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
